BioCentury | Nov 16, 2018
Company News

Covis gains full rights to ciclesonide drugs from AZ

...Covis Pharma S.a.r.l. (Zug, Sweden) will acquire ex-U.S. rights to Alvesco, Omnaris and Zetonna from AstraZeneca...
...of $106 million, is eligible for up to $21 million in sales milestones. Asthma drug Alvesco...
...rhinitis. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Covis Pharma S.a.r.l., Zug, Sweden Business: Inflammation Shannon Lehnbeuter Alvesco, ciclesonide (inhaled) Omnaris...
BioCentury | May 30, 2016
Strategy

Taking Takeda global

...pulmonary disease (COPD) drug Daliresp roflumilast outside the U.S. The pharma also marketed asthma drug Alvesco...
BioCentury | Dec 21, 2015
Company News

Takeda, AstraZeneca deal

...AstraZeneca will acquire Takeda’s core respiratory business, including Daliresp roflumilast, Alvesco ciclesonide, Omnaris ciclesonide nasal spray...
...U.S. to treat nasal symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis. Alvesco...
BioCentury | Dec 17, 2015
Top Story

AZ bulks up China operations, respiratory portfolio

...plc , now Allergan plc (NYSE:AGN). The Takeda deal includes worldwide rights to inhaled corticosteroid Alvesco...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

...somatropin Merck KGaA Both Tev-Tropin somatropin Antares/Teva Both Genotropin somatropin Pfizer CVS Inhaled steroids (asthma) Alvesco...
BioCentury | Sep 3, 2012
Company News

Elevation Pharmaceuticals, Dainippon Sumitomo deal

...Partners. Sunovion said the deal will complement its marketed respiratory portfolio, which includes asthma drug Alvesco...
BioCentury | Aug 31, 2012
Company News

Sunovion to acquire Elevation

...Partners. Sunovion said the deal will complement its marketed respiratory portfolio, which includes asthma drug Alvesco...
BioCentury | Dec 5, 2011
Clinical News

Ciclesonide HFA: Phase III data

...which was acquired by Takeda in September (see BioCentury, Oct. 3). Sunovion already markets Alvesco...
BioCentury | Jul 5, 2010
Clinical News

Omnaris HF ciclesonide: Preliminary Phase III data

...subsidiary has U.S. rights to develop and commercialize ciclesonide from Nycomed. Sepracor already markets the Alvesco...
BioCentury | May 4, 2009
Clinical News

Ciclesonide nasal aerosol: Preliminary Phase III data

...Sepracor has U.S. rights to develop and commercialize ciclesonide from Nycomed. Sepracor already markets the Alvesco...
Items per page:
1 - 10 of 60